References
- Godman B, Bucsics A, Burkhardt T, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8(4), 357–371 (2008).
- Wettermark B, Godman B, Andersson K, Gustafsson LL et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26(7), 537–550 (2008).
- Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26(2), 91–98 (2008).
- Godman B, Wettermark B, Hoffman M, Andersson K, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomcis Outcomes Res.9(1), 65–83 (2009).
- Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27(5), 435–438 (2009).
- Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
- Walley T, Folino-Gallo P, Schwabe U, van Ganse E; EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ328, 385–386 (2004).
- Winkelmayer C, Asslaber M, Brookhart M et al. Impact of reimbursed changes on statin use among patients with diabetes in Austria. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 25 (2009).
- Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7(3), 1–11 (2009).
- Godman B, Vlahovic-Palcevski V, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 37 (2009).
- Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 35 (2009).
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
- Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
- Rydén L, Standl E, Bartnik M et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J.28(1), 88–136 (2007).
- Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study Br. J. Clin. Pharm.64(4), 476–481 (2007).
- Winkelmayer WC, Bucsics AE, Schautzer A, Wieninger P, Pogantsch M; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds. Use of recommended medications after myocardial infarction in Austria. Eur. J. Epidemiol.23(2), 153–162 (2008).
- Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ336, 2–3 (2008).
- Björnsson E, Abrahamsson H, Simrén M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment. Pharmacol Ther24(6), 945–954 (2006).
Websites
- Beishon J, McBride T. Scharaschkin S et al. National Audit Office. Prescribing costs in primary care. 14 May 2007 www.nao.org.uk (Accessed 21 May 2008)
- Simoens S, De Coster S. Sustaining Generic Markets in Europe. Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium (2006) www.egagenerics.com/doc/simoens-report_2006–2004.pdf (Accessed 16 October 2008)
- [Medicines and Reason Initiatives] (in German) www.sozialversicherung.at/arzneiundvernunft (Accessed 3 May 2009)
- Tomas Dolezal. The Czech Republic www.ceestahc.org/pliki/symp2008/dolezal.pdf (Accessed 6 January 2009)
- WHO. Guidelines for ATC Classification and DDD Assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway (2009) www.whocc.no (Accessed 6 January 2009)
- WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization, Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf (Accessed 30 April 2009)
- Eriksson G, Lundin D. The Review of Medicines for Treating Lipid Disorders; a Summary. TLV, Sweden (2009) www.tlv.se/Upload/Genomgangen/summary-lipids.pdf (Accessed 30 March 2009)
- Wessling A, Lundin D. The Review of Drugs Against Disease Caused by Acid Stomach – A Summary. Pharmaceuticals Benefits Board, Solna, Sweden (2006) www.tlv.se/Upload/Genomgangen/summary-stommach-acid.pdf (Accessed 6 January 2009)